TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy

Published:2017-03 Issue:1 Volume:276 Page:165-177
ISSN:0105-2896
Container-title:Immunological Reviews
language:en
Short-container-title:Immunol Rev

Author:

Akalu Yemsratch T.¹,Rothlin Carla V.¹²,Ghosh Sourav²³

Affiliation:

1. Department of Immunobiology; Yale University School of Medicine; New Haven CT USA

2. Department of Pharmacology; Yale University School of Medicine; New Haven CT USA

3. Department of Neurology; Yale University School of Medicine; New Haven CT USA

Funder

National Institutes of Health

National Institute of Allergy and Infectious Diseases

Alliance for Lupus Research

Yale Melanoma SPORE

Yale Cancer Center

Yale Immunobiology Department

Richard K. Gershon Fellowship

HHMI Faculty Scholar Award.

Publisher

Wiley

Subject

Immunology,Immunology and Allergy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/imr.12522/fullpdf

Reference149 articles.

1. Coley's toxins, tumor necrosis factor and cancer research: a historical perspective;Wiemann;Pharmacol Ther,1994

2. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma;Ansell;N Engl J Med,2015

3. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer;Brahmer;N Engl J Med,2012

4. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer;Topalian;N Engl J Med,2012

5. Nivolumab in previously untreated melanoma without BRAF mutation;Robert;N Engl J Med,2015

Cited by 133 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Trend of the Treatment of Advanced Hepatocellular Carcinoma: Combination of Immunotherapy and Targeted Therapy;Current Treatment Options in Oncology;2024-09-11

2. SAFFRON-104: a phase Ib/II study of sitravatinib alone or with tislelizumab in advanced hepatocellular carcinoma and gastric cancer/gastroesophageal junction cancer;Cancer Immunology, Immunotherapy;2024-09-05

3. Pharmacological mechanisms by which baicalin ameliorates cardiovascular disease;Frontiers in Pharmacology;2024-08-09

4. Small-molecule-based targeted therapy in liver cancer;Molecular Therapy;2024-08

5. Systemic treatment options for non-small cell lung cancer after failure of previous immune checkpoint inhibitors: a bayesian network meta-analysis based on randomized controlled trials;BMC Immunology;2024-06-28

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3